Inspire Medical Systems $INSP

Health Care · NYSE

$55.10
-1.18 (-2.10%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Nov 3, 2026, the first target we tracked for INSP.

Inspire Medical Systems (INSP) is trading down at $55.10 (-2.10%) on NYSE, as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: May 3, 2018 · $16.00 offering · NYSE

Analyst price targets on INSP

Current price targets from 3 firms average $76.7, median $76, ranging from $69 to $85 — the average is 39% above the current $55.1. Each is tracked to its date and scored the same way a member's call is.

3 targets, newest first. Open a row for its source and scoring.

DateNov 3, 2026 FirmWells Fargo RatingEqual Weight · raises Targetat $61.9 · $69 +11% Horizonby Nov 2027 StatusOpen

Entry price $61.9, the close nearest Nov 3, 2026, when the target was reported; the target is +11% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 3, 2027.

Source Stifel reiterates Inspire Medical Systems stock rating on Q3 beat Investing.com · Nov 3, 2026 · opens the publisher's site
This revenue performance also beat Wells Fargo’s estimate of $205.2 million, leading the firm to raise its price target on the company’s stock to $69 from $56, while maintaining an Equal Weight rating.
DateNov 3, 2026 FirmTruist Securities RatingHold · lowers Targetat $61.9 · $76 +23% Horizonby Nov 2027 StatusOpen

Entry price $61.9, the close nearest Nov 3, 2026, when the target was reported; the target is +23% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 3, 2027.

Source Stifel reiterates Inspire Medical Systems stock rating on Q3 beat Investing.com · Nov 3, 2026 · opens the publisher's site
Truist Securities, however, lowered its price target for Inspire Medical Systems to $76 from $78, maintaining a Hold rating, based on a revised 2028 revenue estimate.
DateNov 3, 2026 FirmStifel RatingBuy · reiterates Targetat $61.9 · $85 +37% Horizonby Nov 2027 StatusOpen

Entry price $61.9, the close nearest Nov 3, 2026, when the target was reported; the target is +37% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 3, 2027.

Source Stifel reiterates Inspire Medical Systems stock rating on Q3 beat Investing.com · Nov 3, 2026 · opens the publisher's site
Investing.com - Stifel reiterated a Buy rating and $85.00 price target on Inspire Medical Systems stock (NYSE:INSP) following the company’s third-quarter results.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Inspire Medical Systems revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$912.0M$427.4M−$57.2MFY2016 revenue: $16.4MFY2016 net income: −$18.5M · Net margin −112.8%'16FY2017 revenue: $28.6MFY2017 net income: −$17.5M · Net margin −61.3%'17FY2018 revenue: $50.6MFY2018 net income: −$21.8M · Net margin −43.1%'18FY2019 revenue: $82.0MFY2019 net income: −$33.2M · Net margin −40.5%'19FY2020 revenue: $115.4MFY2020 net income: −$57.2M · Net margin −49.6%'20FY2021 revenue: $233.4MFY2021 net income: −$42.0M · Net margin −18.0%'21FY2022 revenue: $407.9MFY2022 net income: −$44.9M · Net margin −11.0%'22FY2023 revenue: $624.8MFY2023 net income: −$21.2M · Net margin −3.4%'23FY2024 revenue: $802.8MFY2024 net income: $53.5M · Net margin 6.7%'24FY2025 revenue: $912.0MFY2025 net income: $145.4M · Net margin 15.9%'250%10%20%30%40%FY2016 net margin: −112.8% (off the scale, which stops at −2.5%)FY2017 net margin: −61.3% (off the scale, which stops at −2.5%)FY2018 net margin: −43.1% (off the scale, which stops at −2.5%)FY2019 net margin: −40.5% (off the scale, which stops at −2.5%)FY2020 net margin: −49.6% (off the scale, which stops at −2.5%)FY2021 net margin: −18.0% (off the scale, which stops at −2.5%)FY2022 net margin: −11.0% (off the scale, which stops at −2.5%)FY2023 net margin: −3.4% (off the scale, which stops at −2.5%)FY2024 net margin: 6.7%FY2025 net margin: 15.9%
Inspire Medical Systems annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$16.4M$28.6M$50.6M$82.0M$115.4M$233.4M$407.9M$624.8M$802.8M$912.0M
Growth (year over year)—+73.9%+77.1%+62.2%+40.6%+102.3%+74.7%+53.2%+28.5%+13.6%
Gross profit$12.5M$22.5M$40.5M$68.4M$97.8M$200.1M$341.7M$528.2M$679.8M$778.8M
Gross margin76.2%78.9%80.1%83.4%84.7%85.7%83.8%84.5%84.7%85.4%
Operating income−$17.3M−$16.0M−$20.4M−$34.9M−$56.2M−$39.9M−$47.6M−$40.3M$36.1M$51.0M
Operating margin−105.0%−56.0%−40.3%−42.5%−48.7%−17.1%−11.7%−6.4%4.5%5.6%
Net income−$18.5M−$17.5M−$21.8M−$33.2M−$57.2M−$42.0M−$44.9M−$21.2M$53.5M$145.4M
Net margin−112.8%−61.3%−43.1%−40.5%−49.6%−18.0%−11.0%−3.4%6.7%15.9%
EPS (diluted)−$16.90−$14.88−$1.50−$1.40−$2.19−$1.54−$1.60−$0.72$1.75$4.89
Balance sheet
Cash and equivalents$6.68M$8.96M$97.3M$22.9M$190.5M$214.5M$441.6M$185.5M$150.2M$104.8M
Total assets—$25.1M$200.1M$181.3M$281.2M$295.1M$564.9M$676.8M$808.4M$907.3M
Total liabilities—$23.8M$36.1M$41.4M$51.4M$66.0M$68.9M$104.3M$118.7M$126.2M
Long-term debt——$24.5M$24.5M$24.5M$24.5M————
Shareholders' equity−$6.61M$1.33M$164.0M$139.8M$229.7M$229.0M$496.0M$572.5M$689.7M$781.2M
Cash flow
Operating cash flow−$17.9M−$15.8M−$18.7M−$32.8M−$53.0M−$20.1M$11.6M$24.7M$130.2M$117.0M
Capital expenditure$306.0K$412.0K$250.0K$2.74M$2.46M$4.67M$9.10M$23.6M$39.1M$38.5M
Free cash flow−$18.3M−$16.2M−$18.9M−$35.6M−$55.5M−$24.8M$2.47M$1.02M$91.1M$78.5M
Share buybacks——————$0$0$0$175.0M

From Inspire Medical Systems's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Inspire Medical Systems in the news

Nov 18, 2026 GlobeNewswire Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case
Nov 17, 2026 GlobeNewswire Inspire Medical Systems, Inc. to Present at the Piper Sandler 38th Annual Healthcare Conference
Nov 3, 2026 Investing.com Stifel reiterates Inspire Medical Systems stock rating on Q3 beat Target
Oct 1, 2026 GlobeNewswire Inspire Medical Systems, Inc. Announces Approval of New Hypoglossal Nerve Stimulation CPT® Codes by the AMA Editorial Panel
Aug 26, 2026 GlobeNewswire Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

About Inspire Medical Systems

Headquarters
Golden Valley, Minnesota From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →